Thermo-reversible flurbiprofen liquid suppository with HP-β-CD as a solubility enhancer: Improvement of rectal bioavailability

Journal of Inclusion Phenomena and Macrocyclic Chemistry

Volumn 64, Issue 3-4, 2009, Pages 265-272

  Kim, Jin Ki ^a   Kim, Myung Sun ^a   Park, Jeong Sook ^b   Kim, Chong Kook ^a,c  

^a Seoul National University   (South Korea)

^b Chungnam National University   (South Korea)

^c Inje University   (South Korea)

Author keywords

Bioavailability; Flurbiprofen; Hydroxypropyl cyclodextrin; Poloxamer; Thermo reversible liquid suppository

Indexed keywords

EID: 70349680609     PISSN: 09230750     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10847-009-9560-7     Document Type: Article

References (35)

1. Lomen, P.L., Turner, L.F., Lamborn, K.R., Winblad, M.A., Sack, R.L., Brinn, E.L.: Flurbiprofen in the treatment of acute gout: a comparison with indomethacin. Am. J. Med. 80, 134-139 (1986). doi:10.1016/0002-9343(86)90131-2.
2. Brown, B.L., Johnson, J.H., Hearron, M.S.: Double-blind comparison of flurbiprofen and sulindac for the treatment of osteoarthritis. Am. J. Med. 80, 112-117 (1986). doi:10.1016/0002-9343(86)90126-9.
3. Richy, F., Rabenda, V., Mawet, A., Reginster, J.Y.: Flurbiprofen in the symptomatic management of rheumatoid arthritis: a valuable alternative. Int. J. Clin. Pract. 61, 1396-1406 (2007). doi:10.1111/j.1742-1241.2007.01452.x.
4. Dalvi, S.S., Gupta, K.C., Pohujani, S.M., Vaidya, A.B., Satoskar, R.S.: Bioavailability of aspirin after oral and rectal administration in volunteers and patients with fever. J. Postgrad. Med. 31, 192-195 (1985).
5. Insel, P.A.: Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Hardman, J.G., Limbird, I.E. (eds.) Goodman & Gilman's the pharmacological basis of therapeutics, pp. 617-658. McGraw-Hill, New York (1996).
6. Kim, C.K., Yoon, Y.S.: Preparation and evaluation of flurbiprofen dry elixir as a novel dosage form using a spray drying technique. Int. J. Pharm. 120, 21-31 (1995). doi:10.1016/0378-5173(94)00375-F.
7. Cirri, M., Rangoni, C., Maestrelli, F., Corti, G., Mura, P.: Development of fast-dissolving tablets of flurbiprofen-cyclodextrin complexes. Drug Dev. Ind. Pharm. 31, 697-707 (2005). doi:10.1080/03639040500253694.
8. Govindarajan, R., Nagarsenker, M.S.: Formulation studies and in vivo evaluation of a flurbiprofen-hydroxypropyl β-cyclodextrin system. Pharm. Dev. Technol. 10, 105-114 (2005). doi:10.1081/PDT-200049687.
9. Gupta, G.D., Jain, S., Jain, N.K.: Formulation of an aqueous injection of flurbiprofen. Pharmazie 52, 709-712 (1997).
10. Habib, M.J., Phan, M.T., Owusu-Ababio, G.: Dissolution profiles of flurbiprofen in phospholipid solid dispersions. Drug Dev. Ind. Pharm. 24, 1077-1082 (1998). doi:10.3109/03639049809089952.
11. Ozeki, T., Beppu, S., Mizoe, T., Takashima, Y., Yuasa, H., Okada, H.: Preparation of two-drug composite microparticles to improve the dissolution of insoluble drug in water for use with a 4-fluid nozzle spray drier. J. Control. Release 107, 387-394 (2005). doi:10.1016/j.jconrel.2005.06.012.
12. Allison, M.C., Howatson, A.G., Torrance, C.J., Lee, F.D., Russell, R.I.: Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 327, 749-754 (1992).
13. Park, K.M., Lee, M.K., Hwang, K.J., Kim, C.K.: Phospholipid-based microemulsions of flurbiprofen by the spontaneous emulsification process. Int. J. Pharm. 183, 145-154 (1999). doi:10.1016/S0378-5173(99)00080-0.
14. Ueki, R., Tanimoto, M., Tatara, T., Tsujimoto, S., Kaminoh, Y., Tashiro, C.: Emulsion of flurbiprofen axetil reduces propofol injection pain due to a decrease in free propofol concentration. J. Anesth. 21, 325-329 (2007). doi:10.1007/s00540-007-0530-1.
15. Charoo, N.A., Shamsher, A.A., Kohli, K., Pillai, K.K., Rahman, Z.: Improvement in bioavailability of transdermally applied flurbiprofen using tulsi (Ocimum sanctum) and turpentine oil. Collioids Surf B Biointerfaces 65, 300-307 (2008). doi:10.1016/j.colsurfb.2008.05.001.
16. Han, F., Li, S., Yin, R., Shi, X., Jia, Q.: Investigation of nanostructured lipid carriers for transdermal delivery of flurbiprofen. Drug Dev. Ind. Pharm. 34, 453-458 (2008). doi:10.1080/03639040701833708.
17. Choi, H.G., Jung, J.H., Ryu, J.M., Yoon, S.J., Oh, Y.K., Kim, C.K.: Development of in situ gelling and mucoadhesive acetaminophen liquid suppository. Int. J. Pharm. 165, 33-44 (1998). doi:10.1016/S0378-5173(97)00386-4.
18. Chang, J.Y., Oh, Y.K., Kong, H.S., Kim, E.J., Jang, D.D., Nam, K.T., Kim, C.K.: Prolonged antifungal effects of clotrimazole mucoadhesive thermosensitive gels on vaginitis. J. Control. Release 85, 39-50 (2002). doi:10.1016/S0168-3659(02)00086-X.
19. Bilensoy, E., Çirpanh, Y., Şen, M., Doǧan, A.L., Çahş, S.: Thermosensitive mucoadhesive gel formulation loaded with 5-Fu: cyclodextrin complex for HPV-induced cervical cancer. J. Incl. Phenom. Macrocycl. Chem. 57, 363-370 (2007). doi:10.1007/s10847-006-9259-y.
20. Kim, C.K., Lee, S.W., Choi, H.G., Lee, M.K., Gao, Z.G., Kim, I.S., Park, K.M.: Trials of in situ gelling and mucoadhesive acetaminophen liquid suppository in human subjects. Int. J. Pharm. 174, 201-207 (1998). doi:10.1016/S0378-5173(98)00258-0.
21. Yun, M.O., Choi, H.G., Jung, J.H., Kim, C.K.: Development of thermo-reversible insulin liquid suppository with bioavailability enhancement. Int. J. Pharm. 189, 137-145 (1999). doi:10.1016/S0378-5173(99)00227-6.
22. El-Kamel, A., El-Khatib, M.: Thermally reversible in situ gelling carbamazepine liquid suppository. Drug Deliv. 13, 143-148 (2006). doi:10.1080/10717540500316003.
23. Yong, C.S., Oh, Y.K., Jung, S.H., Rhee, J.D., Kim, H.D., Kim, C.K., Choi, H.G.: Preparation of ibuprofen-loaded liquid suppository using eutectic mixture system with menthol. Eur. J. Pharm. Sci. 23, 347-353 (2004). doi:10.1016/j.ejps.2004.08.008.
24. Loftsson, T., Brewster, M.E.: Pharmaceutical applications of cyclodextrins I Drug solubilization and stabilization. J. Pharm. Sci 85(10), 1017-1025 (1996). doi:10.1021/js950534b.
25. Thompson, D.O.: Cyclodextrins as enabling excipients: their present and future use in pharmaceuticals. CRC Crit. Rev. Ther. Drug Carr. Syst. 14(1), 1-104 (1997).
26. Yashida, A., Yamamoto, M., Irie, T., Hirayama, F., Uekama, K.: Some pharmaceutical properties of 3-hydroxypropyl and 2, 3-dihydroxypropyl β-cyclodextrins and their solubilizing and stabilizing ability. Chem. Pharm. Bull. (Tokyo) 37, 1059-1063 (1989).
27. Hirayama, F., Mieda, S., Miyamoto, Y., Arima, H., Uekama, K.: Heptakis(2, 6-di-O-methyl-3-O-acetyl)-beta-cyclodextrin: a water-soluble cyclodextrin derivative with low hemolytic activity. J. Pharm. Sci. 88, 970-975 (1999). doi:10.1021/js990128i.
28. Mura, P., Zerrouk, N., Faucci, M., Maestrelli, F., Chemtob, C.: Comparative study of ibuproxam complexation with amorphous beta-cyclodextrin derivatives in solution and in the solid state. Eur. J. Pharm. Biopharm. 54, 181-191 (2002). doi:10.1016/S0939-6411(02)00075-9.
29. Choi, H.G., Lee, B.J., Han, J.H., Lee, M.K., Park, K.M., Yong, C.S., Rhee, J.D., Kim, Y.B., Kim, C.K.: Terfenadine-beta-cyclodextrin inclusion complex with antihistaminic activity enhancement. Drug Dev. Ind. Pharm. 27, 857-862 (2001). doi:10.1081/DDC-100107250.
30. Ricci, E.J., Bentley, M.V., Farah, M., Bretas, R.E., Marchetti, J.M.: Rheological characterization of Poloxamer 407 lidocaine hydrochloride gels. Eur. J. Pharm. Sci. 17, 161-167 (2002). doi:10.1016/S0928-0987(02)00166-5.
31. Bonacucina, G., Spina, M., Misici-Falzi, M., Cespi, M., Pucciarelli, S., Angeletti, M., Palmieri, G.F.: Effect of hydroxypropyl beta-cyclodextrin on the self-assembling and thermogelation properties of Poloxamer 407. Eur. J. Pharm. Sci. 32, 115-122 (2007). doi:10.1016/j.ejps.2007.06.004.
32. Sciesaka, J.F., Vidmar, T.J., Haynes, L.C., Cho, M.J.: Biochemical stability in serum of a lipid-soluble probe molecule entrapped in an o/w emulsion as a carrier for passive drug targeting. Int. J. Pharm. 45, 165-168 (1988). doi:10.1016/0378-5173(88)90047-6.
33. Choi, H.G., Oh, Y.K., Kim, C.K.: In situ gelling and mucoadhesive liquid suppository containing acetaminophen: enhanced bioavailability. Int. J. Pharm. 165, 23-32 (1998). doi:10.1016/S0378-5173(97)00385-2.
34. Davies, N.M.: Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin. Pharmacokinet 28, 100-114 (1995).
35. Shimpi, S., Chauhan, B., Shimpi, P.: Cyclodextrins: application in different routes of drug administration. Acta Pharm. 55, 139-156 (2005).